Dr. Hammers on Immunotherapy Combinations in Kidney Cancer

Hans J. Hammers, MD, PhD
Published: Thursday, Sep 07, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Since nivolumab (Opdivo) has been approved, it has changed the treatment landscape for patients with kidney cancer, states Hammers. However, ongoing studies have been looking to combine nivolumab with other agents to increase the response.

Combining nivolumab with VEGF inhibitors is an area that has shown particular promise, explains Hammers. The trials investigating these combinations have shown encouraging data.



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.

Since nivolumab (Opdivo) has been approved, it has changed the treatment landscape for patients with kidney cancer, states Hammers. However, ongoing studies have been looking to combine nivolumab with other agents to increase the response.

Combining nivolumab with VEGF inhibitors is an area that has shown particular promise, explains Hammers. The trials investigating these combinations have shown encouraging data.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x